Pramlintide (Symlin)
A mealtime injection that curbs appetite and steadies blood sugar in diabetics. A synthetic analog of amylin (the satiety hormone co-secreted with insulin), FDA-approved in 2005 as a mealtime adjunct in type 1 and type 2 diabetes, and the clinical predecessor to Cagrilintide.
Pramlintide (Symlin): A mealtime injection that curbs appetite and steadies blood sugar in diabetics. A synthetic analog of amylin (the satiety hormone co-secreted with insulin), FDA-approved in 2005 as a mealtime adjunct in type 1 and type 2 diabetes, and the clinical predecessor to Cagrilintide. Pramlintide (sold as Symlin) is the synthetic copy of amylin, a satiety hormone your pancreas releases alongside insulin.
Pramlintide (sold as Symlin) is the synthetic copy of amylin, a satiety hormone your pancreas releases alongside insulin. FDA-approved as a mealtime injection for diabetes. It's the predecessor to Cagrilintide, just shorter-acting and used differently.
Yes, endocrinology providers prescribe in insulin-using diabetes contexts.
Who it's for
- →T1D or T2D patients struggling with post-meal glucose spikes
- →Mealtime-insulin users wanting better satiety
- →Educational reference for amylin pathway
What to expect
- Week 1
Post-meal glucose excursions reduce. Satiety improves.
- Week 4
Insulin requirements often drop 30-50%.
- Week 8
Stable adjunct effect.
Looking at Pramlintide (Symlin)? Your next 3 steps
- 1Work out your exact dose
Vial size + BAC water turns into the exact units to draw for Pramlintide (Symlin).
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account saves your stack; membership adds the stack-aware AI Coach.
Create free account →
How it works (mechanism)
Synthetic amylin analog with three proline substitutions to prevent the aggregation that limits native amylin's drug suitability. Slows gastric emptying and reduces post-meal glucagon.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- ⚠Hypoglycemia unawareness
- ⚠Gastroparesis
- ⚠A1C > 9%
- ⚠Pregnancy / nursing
Bloodwork to monitor
- • A1C
- • Glucose monitoring
- • Fasting insulin if on insulin therapy
Common mistakes
- • Not reducing mealtime insulin by 50% on first dose (causes severe hypoglycemia)
- • Using it for non-diabetic weight loss (off-label, less effective than Cagrilintide)
- • Skipping the pre-meal timing
Drug & supplement interactions
- ⚠MUST reduce mealtime insulin by 50% on first dose to prevent severe hypoglycemia (boxed warning)
- ⚠Drugs that delay gastric emptying (anticholinergics) compound the slowing effect
- ⚠Oral medications requiring rapid absorption: dose 1 hour before pramlintide
Community patterns
New to Pramlintide (Symlin)? Grab the starter checklist.
Drop your email and we'll send the one-page first-cycle starter checklist, plus a heads-up if Pramlintide (Symlin) changes legal status. No account needed.
No spam. No selling your email. Just the checklist and the occasional reclassification alert.
Ask the Coach anything about Pramlintide (Symlin) or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Get the Coach, $7.99/mo →Frequently asked
What is Pramlintide (Symlin)?+
Is Pramlintide (Symlin) FDA approved?+
Is Pramlintide (Symlin) legal?+
Is Pramlintide (Symlin) banned by WADA?+
Are you still natty after taking Pramlintide (Symlin)?+
Do doctors prescribe Pramlintide (Symlin)?+
What's the typical dose of Pramlintide (Symlin)?+
What are the side effects of Pramlintide (Symlin)?+
How long until Pramlintide (Symlin) starts working?+
What can you stack with Pramlintide (Symlin)?+
Where do people get Pramlintide (Symlin)?+
More in Fat Loss
Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound.
The original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist.
Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.
Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.